Enliven Therapeutics's total assets for Q3 2023 were $274.04M, a decrease of -5.01% from the previous quarter. ELVN total liabilities were $12.29M for the fiscal quarter, a 29.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.